Diagnosis & Disease Information

Plasma tumor DNA (ptDNA) is superior to serum for analyzing the DNA shed by tumors into the bloodstream.

Circulating free tumor DNA techniques might improve the ability to match tumor mutations to genotype-matched targeted therapies.

BARD1, RAD51D, and MSH6 gene variants increase breast cancer risk.

Higher tumor-infiltrating lymphocyte (TIL) values in tumor stroma are associated with longer overall survival (OS).

Gene mutation status is prognostic for postmenopausal women with early-stage estrogen receptor-positive (ER+) breast cancer.

Several mechanism-of-action-based biomarkers predict high-risk HER2-negative breast cancer response to combination therapy.

Adding veliparib to carboplatin and paclitaxel for patients with advanced BRCA mutation-associated breast cancer is safe but did not improve survival.

Extending adjuvant anastrozole therapy from 3 to 6 years after up to 3 years of tamoxifen does not improve breast cancer survival outcomes.